Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19

Br J Haematol. 2021 Aug;194(3):549-553. doi: 10.1111/bjh.17517. Epub 2021 Jun 7.
No abstract available

Keywords: AML; COVID-19; children; induction chemotherapy; serology.

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Adolescent
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antimalarials / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • COVID-19 / complications*
  • COVID-19 / diagnosis
  • COVID-19 / immunology
  • COVID-19 Drug Treatment
  • Disease Management
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Hydroxyurea / therapeutic use
  • Leukemia, Myeloid, Acute / complications*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / immunology
  • Male
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / isolation & purification
  • Young Adult

Substances

  • Antimalarials
  • Antineoplastic Agents
  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Hydroxychloroquine
  • Alanine
  • Hydroxyurea